

Special Issue

Advance and New Insights in Bladder Cancer

Message from the Guest Editor

The potential readership of this special issue will expand their knowledge on the pathology and the molecular landscape in BCa and its treatment consequences, including variant (aberrant) pathologies, the molecular classification of BCa and the genomic approach in BCa. They will also be updated on diagnostics and staging of BCa, and learn about NMIBC, specifically endoscopic diagnosis and therapy, treatment optimisation and the role of local and new systemic approaches and their optimal timing. When it comes to MIBC, participants will learn specifically about surgery (both the role of TURB and Open vs. Robotics), about systemic therapy (neoadjuvant and adjuvant systemic chemotherapy and immunotherapy), and the bladder-sparing approach. Finally, participants will have been instructed on systemic therapy in metastatic bladder and urothelial cancer and have developed an understanding on BCa recurrence and follow-up.

Guest Editor

Prof. Dr. Morgan Rouprêt
Sorbonne Université, GRC n5, ONCOTYPE-URO, AP-HP, Urology,
Hôpital Pitié-Salpêtrière, 75013 Paris, France

Deadline for manuscript submissions

closed (30 October 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/101020

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)